155 related articles for article (PubMed ID: 27260088)
1. Effect of solubility enhancement on nasal absorption of meloxicam.
Horváth T; Ambrus R; Völgyi G; Budai-Szűcs M; Márki Á; Sipos P; Bartos C; Seres AB; Sztojkov-Ivanov A; Takács-Novák K; Csányi E; Gáspár R; Szabó-Révész P
Eur J Pharm Sci; 2016 Dec; 95():96-102. PubMed ID: 27260088
[TBL] [Abstract][Full Text] [Related]
2. Study of sodium hyaluronate-based intranasal formulations containing micro- or nanosized meloxicam particles.
Bartos C; Ambrus R; Sipos P; Budai-Szűcs M; Csányi E; Gáspár R; Márki Á; Seres AB; Sztojkov-Ivanov A; Horváth T; Szabó-Révész P
Int J Pharm; 2015 Aug; 491(1-2):198-207. PubMed ID: 26142244
[TBL] [Abstract][Full Text] [Related]
3. Investigation of Absorption Routes of Meloxicam and Its Salt Form from Intranasal Delivery Systems.
Bartos C; Ambrus R; Kovács A; Gáspár R; Sztojkov-Ivanov A; Márki Á; Janáky T; Tömösi F; Kecskeméti G; Szabó-Révész P
Molecules; 2018 Mar; 23(4):. PubMed ID: 29597330
[TBL] [Abstract][Full Text] [Related]
4. A novel transdermal patch incorporating meloxicam: in vitro and in vivo characterization.
Ah YC; Choi JK; Choi YK; Ki HM; Bae JH
Int J Pharm; 2010 Jan; 385(1-2):12-9. PubMed ID: 19833177
[TBL] [Abstract][Full Text] [Related]
5. Improved absorption of meloxicam via salt formation with ethanolamines.
Han HK; Choi HK
Eur J Pharm Biopharm; 2007 Jan; 65(1):99-103. PubMed ID: 16919925
[TBL] [Abstract][Full Text] [Related]
6. Formulation and evaluation of meloxicam oral disintegrating tablet with dissolution enhanced by combination of cyclodextrin and ion exchange resins.
Samprasit W; Akkaramongkolporn P; Ngawhirunpat T; Rojanarata T; Opanasopit P
Drug Dev Ind Pharm; 2015 Jun; 41(6):1006-16. PubMed ID: 24865111
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetics of meloxicam administered as regular and fast dissolving formulations to the rat: influence of gastrointestinal dysfunction on the relative bioavailability of two formulations.
Aghazadeh-Habashi A; Jamali F
Eur J Pharm Biopharm; 2008 Nov; 70(3):889-94. PubMed ID: 18715548
[TBL] [Abstract][Full Text] [Related]
8. [Stability testing of meloxicam-containing microcomposites for inhalation].
Pomázi A; Ambrus R; Szabóné Révész P
Acta Pharm Hung; 2014; 84(2):55-62. PubMed ID: 25167700
[TBL] [Abstract][Full Text] [Related]
9. Semi solid matrix formulations of meloxicam and tenoxicam: an in vitro and in vivo evaluation.
Alladi S; Shastri NR
Arch Pharm Res; 2015; 38(5):801-12. PubMed ID: 24752862
[TBL] [Abstract][Full Text] [Related]
10. Evaluating bioequivalence of meloxicam tablets: is in-vitro dissolution test overdiscriminating?
Jin C; Zhao C; Shen D; Dong W; Liu H; He Z
J Pharm Pharmacol; 2018 Feb; 70(2):250-258. PubMed ID: 29193077
[TBL] [Abstract][Full Text] [Related]
11. Cyclodextrin-based oral dissolving films formulation of taste-masked meloxicam.
Samprasit W; Akkaramongkolporn P; Kaomongkolgit R; Opanasopit P
Pharm Dev Technol; 2018 Jun; 23(5):530-539. PubMed ID: 29103353
[TBL] [Abstract][Full Text] [Related]
12. Bovine serum albumin-meloxicam nanoaggregates laden contact lenses for ophthalmic drug delivery in treatment of postcataract endophthalmitis.
Zhang W; Zu D; Chen J; Peng J; Liu Y; Zhang H; Li S; Pan W
Int J Pharm; 2014 Nov; 475(1-2):25-34. PubMed ID: 25158220
[TBL] [Abstract][Full Text] [Related]
13. In vitro and in vivo characterization of meloxicam nanoparticles designed for nasal administration.
Kürti L; Gáspár R; Márki Á; Kápolna E; Bocsik A; Veszelka S; Bartos C; Ambrus R; Vastag M; Deli MA; Szabó-Révész P
Eur J Pharm Sci; 2013 Sep; 50(1):86-92. PubMed ID: 23542493
[TBL] [Abstract][Full Text] [Related]
14. Strategies for meloxicam delivery to and across the skin: a review.
Chen J; Gao Y
Drug Deliv; 2016 Oct; 23(8):3146-3156. PubMed ID: 26956920
[TBL] [Abstract][Full Text] [Related]
15. Powdered self-emulsified lipid formulations of meloxicam as solid dosage forms for oral administration.
Agarwal V; Alayoubi A; Siddiqui A; Nazzal S
Drug Dev Ind Pharm; 2013 Nov; 39(11):1681-9. PubMed ID: 23072611
[TBL] [Abstract][Full Text] [Related]
16. Formulation of meloxicam gel for topical application: In vitro and in vivo evaluation.
Bachhav YG; Patravale VB
Acta Pharm; 2010 Jun; 60(2):153-63. PubMed ID: 21134852
[TBL] [Abstract][Full Text] [Related]
17. Effect of inclusion complexation of meloxicam with β-cyclodextrin- and β-cyclodextrin-based nanosponges on solubility, in vitro release and stability studies.
Shende PK; Gaud RS; Bakal R; Patil D
Colloids Surf B Biointerfaces; 2015 Dec; 136():105-10. PubMed ID: 26364091
[TBL] [Abstract][Full Text] [Related]
18. Development of meloxicam in situ implant formulation by quality by design principle.
Ibrahim HM; Ahmed TA; Hussain MD; Rahman Z; Samy AM; Kaseem AA; Nutan MT
Drug Dev Ind Pharm; 2014 Jan; 40(1):66-73. PubMed ID: 23298324
[TBL] [Abstract][Full Text] [Related]
19. An approach for rapid development of nasal delivery of analgesics--identification of relevant features, in vitro screening and in vivo verification.
Wang S; Chow MS; Zuo Z
Int J Pharm; 2011 Nov; 420(1):43-50. PubMed ID: 21871544
[TBL] [Abstract][Full Text] [Related]
20. Enhancement of the dissolution and permeation rates of meloxicam by formation of its freeze-dried solid dispersions in polyvinylpyrrolidone K-30.
El-Badry M; Fathy M
Drug Dev Ind Pharm; 2006 Feb; 32(2):141-50. PubMed ID: 16537195
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
